Anaplasma phagocytophilum antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Anaplasma phagocytophilum antibodies pairs and antigen for animal health (animal Cat/Feline infectious disease Anaplasmosis) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Companion Animal disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P002-Ag01	Recombinant Anaplasma phagocytophilum protein	$3090.00
GMP-VT-P002-Ab01	Anti-Anaplasma phagocytophilum mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P002-Ab02	Anti-Anaplasma phagocytophilum mouse monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P002-Ag01
Product Name	Recombinant Anaplasma phagocytophilum protein
Pathogen	Anaplasma phagocytophilum
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Anaplasma phagocytophilum antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Anaplasma phagocytophilum level test of animal Cat/Feline infectious disease with Anaplasmosis.
Tag	His
Product description	Recombinant Anaplasma phagocytophilum proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P002-Ab01,GMP-VT-P002-Ab02
Pathogen	Anaplasma phagocytophilum
Product Name	Anti-Anaplasma phagocytophilum mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Anaplasma phagocytophilum antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Anaplasma phagocytophilum antibodies in Anaplasma phagocytophilum level test of animal Cat/Feline infectious disease with Anaplasmosis.
Product description	Anti-Anaplasma phagocytophilum mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Anaplasma phagocytophilum antibodies./td>
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen

Anaplasma phagocytophilum is a gram-negative, obligate intracellular bacterium that was initially discovered in 1990 in Ixodes scapularis ticks, formerly known as I. dammini. Anaplasma phagocytophilum belongs to the family Anaplasmataceae and order Rickettsiales. The pathogen primarily affects ruminant animals, rodents, and deer, but can also infect humans, causing human granulocytic anaplasmosis (HGA).

Anaplasma phagocytophilum features several critical genes and proteins. The msp2 gene encodes for the major surface protein 2, which plays a crucial role in the pathogen's virulence and adaptation to host environments. The gene is responsible for encoding the outer membrane protein (OMP), which is required for adhesion to host cells. The OMPs of Anaplasma phagocytophilum include Anaplasma Phagocytophilum Surface Protein A (ApsA), Outer Membrane Protein A (OmpA), and Major Surface Protein 4 (Msp4), among others.

In addition to OMPs, Anaplasma phagocytophilum has been shown to possess effector proteins that are essential for bacterial survival and replication in the host cell environment. These proteins include ankA and apsB, among others. AnkA facilitates the manipulation of host cellular processes such as signaling pathways, transcriptional regulation, and immune evasion. On the other hand, apsB is an essential component of the type IV secretion system (T4SS), which enables the bacterium to deliver effector proteins to host cells.

Anaplasma phagocytophilum is primarily transmitted via tick bites. Ticks acquire the bacterium during feeding on infected hosts and subsequently transmit it to other hosts, including humans. The bacterium's lifecycle comprises both mammalian and tick stages, with a complex transmission dynamic that involves the exchange of Anaplasma phagocytophilum between hosts via the tick vector.

Anaplasma phagocytophilum is responsible for several diseases, including tick-borne fever (TBF), tick-borne fever of sheep (TBFS), and human granulocytic anaplasmosis (HGA). TBF and TBFS are the most common clinical manifestations of Anaplasma phagocytophilum infection in ruminant animals. These diseases present with symptoms such as fever, anorexia, lethargy, and decreased milk yield. In rare cases, TBF can cause severe illness and mortality. HGA is a zoonotic disease that affects humans, causing flu-like symptoms that include high fever, headache, muscle aches, and fatigue. In severe cases, HGA can lead to complications such as renal failure, respiratory distress, and death.

Diagnostic methods for Anaplasma phagocytophilum include PCR and serological testing. PCR targets specific genes, such as the highly conserved regions of the 16S rRNA gene and the msp2 gene. Serological testing detects antibodies against the bacterium's surface-exposed proteins, such as major surface protein (MSP) and outer membrane protein (OMP). Other diagnostic methods include microscopy, isolation and culture, and immunohistochemistry.

Treatment for Anaplasma phagocytophilum infections typically involves the administration of antibiotics, such as doxycycline or rifampin, for seven to ten days. Additionally, supportive therapy may be required to manage symptoms and prevent complications. In severe cases of HGA, hospitalization may be necessary.

In conclusion, Anaplasma phagocytophilum is a significant pathogen that affects both animals and humans. Its complex transmission dynamics and various clinical manifestations make it a challenging disease to diagnose and treat. However, advances in diagnostic methods and treatment approaches have improved the prognosis for individuals affected by Anaplasma phagocytophilum infections. Further research is necessary to elucidate the mechanisms of pathogenesis and develop new therapeutic interventions.

About GDU